VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company committed to developing differentiated new generation medications for central nervous system (CNS) diseases and disorders with high unmet need. Our product candidate portfolio includes three differentiated clinical-stage candidates, PH94B, PH10 and AV-101, which we are developing for multiple CNS indications. Each of VistaGen’s drug candidates has a fundamentally different mechanism of action from all currently approved oral drug treatments, and potential for rapid onset therapeutic effects, convenient at-home self-administration, and an exceptional safety profile. We aim to become a fully-integrated biopharmaceutical company that develops and commercializes innovative CNS therapies for large and growing mental health and neurology markets where current treatments are inadequate to meet the needs of millions of patients and caregivers worldwide.
343 Allerton Avenue
South San Francisco, CA 94080
Pharmaceutical Preparation Manufacturing (325412)
Pharmaceutical Preparations (2834)